Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00456859
Other study ID # CAP-KD ver.3
Secondary ID
Status Completed
Phase Phase 4
First received April 4, 2007
Last updated October 17, 2007
Start date April 2004
Est. completion date September 2007

Study information

Verified date October 2007
Source Institute for Health Outcomes and Process Evaluation Reseach
Contact n/a
Is FDA regulated No
Health authority Japan: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The CAP-KD trial is a prospective, multicenter, randomized, open-label, two-arm, parallel group comparison clinical trial and will be conducted as a researcher-directed study to assess the efficacy of Kremezin in preventing the progression of CKD. We compare two groups of patients: those receiving conventional treatment alone and those receiving such treatment paired with Kremezin.


Description:

A clinical trial to evaluate the efficacy of the oral carbonaceous adsorbent Kremezin in preventing the progression of chronic kidney disease (the Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease [CAP-KD] trial) in predialysis patients. In the trial we are comparing two treatments: conventional treatment comprising an ACEI and/or ARB together with a low-protein diet, and combination treatment comprising the conventional treatment paired with Kremezin. Furthermore, we will compare the QOL in both groups of patients


Recruitment information / eligibility

Status Completed
Enrollment 450
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- The subject is an outpatient.

- The subject is 20 years of age or older at the time of consent to participate in the study.

- The subject's serum creatinine value is 5.0 mg/dl or less at the time of case registration.

- The inverse serum creatinine value, calculated using measurements at four or more time points during an observation period that occurs within 48 weeks of case registration, is decreasing, on average, according to linear-regression analysis performed at the case registration center.

- The subject's blood pressure is well controlled before the initial serum creatinine measurement during the observation period.

- The subject has been treated with an ACEI and/or ARB before the initial serum creatinine measurement during the observation period.

- The subject has undergone low-protein diet therapy (> 0.8 g/kg per day) before the initial serum creatinine measurement during the observation period.

- The subject has not changed the type or dose of medication for renal failure for 4 weeks prior to case registration.

- The subject has participated in thorough consultation and has been informed as to the purpose, description, expected adverse effects, and risks of this study according to the consent form, and has voluntarily signed the informed consent form.

Exclusion Criteria:

- The subject has a passage disorder of the gastrointestinal tract.

- The subject has been treated with Kremezin within the period from the initial measurement of the serum creatinine level prior to case registration to the time of study commencement.

- The subject has rapid progressive glomerular nephritis, hydronephrosis, occlusive urinary tract injury, drug-induced nephropathy, or transplanted kidney.

- The subject has complications such as severe hepatopathy, liver cirrhosis, severe infection, class III or above New York Heart Association (NYHA) congestive heart failure, severe arrhythmia, or unstable angina.

- The subject has had cardiac infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months.

- The subject presents with severe nephrotic syndrome (serum albumin < 2 g/dl).

- The subject is currently pregnant, or plans to become pregnant during the study period.

- The subject abuses alcohol.

- The subject has a body weight less than 80% or more than 160% of the standard weight {[height(m)]^2 x 22}.

- The subject has significant difficulty in controlling his/her blood sugar level within 3 months of case registration (hemoglobin [Hb]A1c > 8.0% on one occasion).

- The subject has a progressive malignant tumor.

- The subject is not available for study visits at least once per 2 months to provide urine samples.

- The subject is inappropriate for participation in the study for other reasons, as determined by an investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Kremezin


Locations

Country Name City State
Japan iHope International Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Institute for Health Outcomes and Process Evaluation Reseach

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Morita S, Fukuhara S, Akizawa T, Asano Y, Kurokawa K. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol. 2005 Sep;9(3):219-27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The composite primary endpoint comprises the following events:
Primary Doubling of serum Creatinine
Primary Increase in serum Creatinine to 6.0 mg/dl or more
Primary Endstage renal disease (ESRD; defined as that requiring dialysis or renal transplantation)
Primary Death
Secondary Variation in urinary protein
Secondary Changes in Creatinine Clearance
Secondary Changes in health-related quality of life (HRQOL)
Secondary Occurrence of adverse events
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT02922361 - Spending and Outcomes for Complex Medicare Advantage Patients
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Completed NCT01922843 - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis Phase 2
Completed NCT01930396 - Use of Tinzaparin for Anticoagulation in Hemodialysis Phase 4
Not yet recruiting NCT01674660 - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients N/A
Not yet recruiting NCT01157260 - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Phase 4
Completed NCT01209403 - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Phase 4
Completed NCT00753116 - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension Phase 1
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Completed NCT00528788 - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Phase 4
Completed NCT00534144 - Comparison Between Effects of Two Iron Preparations on Protein in the Urine Phase 1
Completed NCT00382044 - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients N/A
Completed NCT00226902 - Vascular Reactivity in Kidney Disease Patients N/A
Recruiting NCT00235287 - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Phase 4
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00071214 - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis Phase 3
Completed NCT00049907 - Cardiac and Renal Disease Study (CARDS) N/A
Completed NCT00006297 - Risk Factors for CV Disease in a Dialysis Cohort N/A

External Links